We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+25.98%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
Cap. Flow
+$59.1M
Cap. Flow %
3.53%
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$23.2M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$20.3M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.6M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$13.3M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Top Sells

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.6M
2
PCVX icon
Vaxcyte
PCVX
+$11M
3
RNAM
Avidity Biosciences
RNAM
+$7.67M
4
COGT icon
Cogent Biosciences
COGT
+$7.55M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELVN icon
26
Enliven Therapeutics
ELVN
$4.24B
$17M 1.01%
830,983
– –
ORIC icon
27
Oric Pharmaceuticals
ORIC
$1.37B
$16.6M 0.99%
+2,142,855
New +$12.2M
TRVI icon
28
Trevi Therapeutics
TRVI
$2.39B
$16.4M 0.98%
6,881,090
+217,500
+3% +$548K
MORF
29
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$15.2M 0.91%
265,511
+51,271
+24% +$2.68M
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$12.5M 0.75%
393,000
– –
RETA
31
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.2M 0.61%
+100,430
New +$9.5M
MGNX icon
32
MacroGenics
MGNX
$263M
$9.65M 0.58%
1,803,204
+100,000
+6% +$617K
REPL icon
33
Replimune Group
REPL
$1.46B
$8.98M 0.54%
386,762
-300,000
-44% -$5.86M
AUTL
34
Autolus Therapeutics
AUTL
$623M
$8.92M 0.53%
3,746,857
– –
PRTA icon
35
Prothena Corp
PRTA
$479M
$8.73M 0.52%
127,900
– –
NTLA icon
36
Intellia Therapeutics
NTLA
$1.8B
$8.31M 0.5%
203,684
– –
ARVN icon
37
Arvinas
ARVN
$600M
$7.08M 0.42%
285,331
– –
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.64B
$5.8M 0.35%
749,022
+66,561
+10% +$561K
IMVT icon
39
Immunovant
IMVT
$8.51B
$5.69M 0.34%
300,000
-285,759
-49% -$5.33M
BLUE
40
DELISTED
bluebird bio
BLUE
$5.63M 0.34%
85,495
+13,457
+19% +$984K
DCPH
41
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.21M 0.31%
+370,000
New +$5.29M
SLN
42
Silence Therapeutics
SLN
$834M
$4.85M 0.29%
881,173
– –
GRTS
43
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$4.68M 0.28%
2,401,714
-2,760,634
-53% -$6.46M
STRO icon
44
Sutro Biopharma
STRO
$339M
$3.63M 0.22%
78,000
-99,648
-56% -$4.96M
ADCT icon
45
ADC Therapeutics
ADCT
$146M
$3.54M 0.21%
1,647,030
– –
ACRS icon
46
Aclaris Therapeutics
ACRS
$885M
$2.74M 0.16%
264,377
– –
PASG icon
47
Passage Bio
PASG
$14.5M
$1.74M 0.1%
92,500
-95,346
-51% -$1.89M
NAMSW icon
48
NewAmsterdam Pharma Warrant
NAMSW
$1.05M 0.06%
500,333
– –
ALLK
49
DELISTED
Allakos
ALLK
– –
-1,112,684
Closed -$4.95M
RNAM
50
DELISTED
Avidity Biosciences
RNAM
– –
-500,000
Closed -$7.67M
1
2
3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2023 Portfolio in Review

As of Q2 2023, Frazier Life Sciences Management held 53 positions worth $1.67B, up 21% from $1.38B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management deployed $59.1M of net new capital in Q2 2023, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Disc Medicine: 655,000 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $11M trimmed.

  • Frazier Life Sciences Management's largest Q2 2023 buy was Disc Medicine: 655,000 shares worth $29.1M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q2 2023, an estimated $20.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $11M.
  • Frazier Life Sciences Management fully exited VectivBio Holding AG Ordinary Shares in Q2 2023, selling an estimated $11.6M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.67B portfolio in Q2 2023.
  • Frazier Life Sciences Management opened 4 new positions and closed 5 in Q2 2023.
  • Frazier Life Sciences Management's portfolio value rose 21% quarter-over-quarter to $1.67B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.